Fast Five Quiz: Non–Small Cell Lung Cancer (NSCLC) and RET Mutation

Maurie Markman, MD

Disclosures

August 24, 2021

Selpercatinib and pralsetinib are selective inhibitors that target RET alterations regardless of the tissue of origin. Selpercatinib was the first targeted therapy to be approved by the US Food and Drug Administration for tumors with RET mutations and is presently indicated for metastatic RET fusion–positive NSCLC. Accelerated approval in May 2020 for NSCLC was based on the open-label LIBRETTO-001 phase 1/2 clinical trial (N = 144). Objective response rate was 64% in treatment-experienced patients (N = 105) and 85% in treatment-naive patients (N = 39). The phase 3 confirmatory trial (LIBRETTO-431) is currently active.

When multitargeted TKIs were investigated for RET-altered NSCLC, response rates were modest and of limited duration. Toxicity could also be significant. RET fusions have also shown minimal response to immunotherapy. However, a pemetrexed-based chemotherapy regimen has been associated with modest activity in patients with RET-rearranged NSCLC.

Learn more about NSCLC treatment.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....